Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in Chronic Immune Thrombocytopenia (ITP)
NCT00049725Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Nov 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclizumab in immune thrombocytopenia (ITP), sponsored by National Institutes of Health. Started Nov 2002; status: completed.
02
Drugs
daclizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00049725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049725.